PubRank

Emmanuel Katsanis

Author PubWeight™ 39.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 2007 2.08
2 Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2006 1.53
3 Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol 2008 1.44
4 Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 2013 1.42
5 Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 2002 1.34
6 Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2002 1.16
7 Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 2009 1.10
8 Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011 1.09
9 Personalized dendritic cell-based tumor immunotherapy. Immunotherapy 2010 1.08
10 Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003 1.05
11 Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol 2012 1.00
12 Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003 0.99
13 The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011 0.99
14 Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 2006 0.91
15 Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. J Immunol 2010 0.89
16 Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood 2010 0.88
17 Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. Int J Cancer 2006 0.88
18 Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism. J Immunol 2011 0.87
19 Late effects in adult survivors of pediatric cancer: a guide for the primary care physician. Am J Med 2012 0.86
20 Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother 2005 0.84
21 The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res 2007 0.83
22 Cytotoxic dendritic cells generated from cancer patients. J Immunol 2011 0.83
23 Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol 2013 0.82
24 Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer 2004 0.82
25 Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood 2004 0.82
26 Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. J Biomed Biotechnol 2004 0.81
27 Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J Leukoc Biol 2008 0.81
28 Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literature. J Pediatr Hematol Oncol 2014 0.81
29 Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology 2009 0.80
30 A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol Cancer Ther 2008 0.80
31 Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res 2004 0.80
32 Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Int J Hyperthermia 2008 0.79
33 Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol Blood Marrow Transplant 2006 0.79
34 The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int J Hyperthermia 2013 0.78
35 Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J 2007 0.78
36 Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. Oncoimmunology 2012 0.77
37 Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunol Immunother 2005 0.77
38 Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy. Pediatr Blood Cancer 2014 0.77
39 Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperthermia 2013 0.76
40 Diagnostic and treatment challenges for the pediatric hematologist oncologist in endemic areas for coccidioidomycosis. J Pediatr Hematol Oncol 2012 0.76